Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
DxUpClose, Inc. logo — Delivering rapid antibiotic sensitivity results directly to...

DxUpClose, Inc.

Delivering rapid antibiotic sensitivity results directly to healthcare professionals, ensuring optimal patient care within sixty minutes.

Founded 2009 United States United States 1 employees Series A Total: $1.00M Biotechnology, Health Care +1

General Information

Company Name DxUpClose, Inc.
Founded Year 2009
Location United States United States
Employees 1
Industries Biotechnology, Health Care, Medical Devices
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with DxUpClose, Inc.. To contact DxUpClose, Inc., visit dxupclose.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does DxUpClose, Inc. compare?

A PDF of DxUpClose, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting DxUpClose, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About DxUpClose, Inc.

DxUpClose, Inc. is an emerging company specializing in the development of a point-of-care bacterial diagnostic device capable of performing an antibiotic sensitivity test in just sixty minutes. The company's slogan "Delivering rapid antibiotic sensitivity results directly to healthcare professionals, ensuring optimal patient care within sixty minutes" encapsulates its core mission. The device is engineered to detect specific bacteria in a sample, count the bacteria present, and conduct antibiotic sensitivity tests—all within an hour. Upon completing the test, it securely sends a list of effective antibiotics to the healthcare provider's email or smartphone, enabling rapid interpretation by a physician who can then prescribe the appropriate antibiotic. This innovation aims to reduce the current delay in optimal patient care from one to three days. DxUpClose, Inc. was founded in 2009 and is headquartered in the United States. In terms of investment, the company received a $1.00M Series A investment on 15 August 2012 from Golden Seeds, one of the pioneering investors in early-stage companies. The device is designed to weigh less than sixteen ounces, fit in a pocket, run on batteries, and endure temperature extremes, making it highly portable without sacrificing diagnostic accuracy. DxUpClose, Inc. operates in the Biotechnology, Health Care, and Medical Devices industries, and its innovative approach has the potential to significantly impact healthcare delivery by providing rapid and accurate antibiotic sensitivity results directly to healthcare professionals, ultimately ensuring optimal patient care within a remarkably short timeframe.

Business keywords: point-of-care diagnostics, bacterial detection, antibiotic sensitivity testing, rapid results, in vitro diagnostics, microbiology, portable diagnostics, patient care optimization

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $1.00M 1
Golden Seeds
Golden Seeds
15 Aug 2012
Seed Round Undisclosed 1
Green Park & Golf Ventures
Green Park & Golf Ventures
25 Jan 2012

DxUpClose, Inc. Alternatives & Competitors

View All Alternatives
DxUpClose, Inc. vs
Xagenic
Xagenic

Empowering clinicians with rapid, near-patient molecular testing for improved patient care and reduc...

Series B
Biotechnology, Health Care
DxUpClose, Inc. vs
Astek Diagnostics
Astek Diagnostics United States

One-hour antibiotic sensitivity testing

Non Equity Assistance
14 employees
Health Care, Medical Devices
DxUpClose, Inc. vs
GeneCapture, Inc.
GeneCapture, Inc. United States

Reinventing Pathogen Detection

Grant
25 employees
Biotechnology, Health Care
Also compare with: DxUpClose, Inc. vs LightDeck Diagnostics LightDeck Diagnostics View all alternatives

FAQ About DxUpClose, Inc.

Delivering rapid antibiotic sensitivity results directly to healthcare professionals, ensuring optimal patient care within sixty minutes.
DxUpClose, Inc. was founded in 2009.
DxUpClose, Inc. is headquartered in United States.
DxUpClose, Inc. operates in Biotechnology, Health Care and Medical Devices. Its work centres on point-of-care diagnostics, bacterial detection, antibiotic sensitivity testing and rapid results.
DxUpClose, Inc. has approximately 1 employees.
DxUpClose, Inc. has completed 2 funding rounds, raising a total of $1.00M. The latest funding stage is Series A.
Top alternatives and competitors to DxUpClose, Inc. include Xagenic, Astek Diagnostics, GeneCapture, Inc., Syntron Bioresearch, Inc., Pathnostics - A Diagnostics Solutions Company. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
DxUpClose, Inc. and Xagenic are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for DxUpClose, Inc., https://bouncewatch.com/company/dxupclose-inc, updated 11 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes